APMD
Apnimed, Inc.
Healthcare — Biotechnology
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
None
$22.54
+$0.63 (+2.88%)
Price History
52-Week Range
Sign in to add APMD to a watchlist or set price alerts.
Fundamentals
| Market Cap | $981.53M |
| P/E Ratio (TTM) | 8.47 |
| Forward P/E | - |
| EPS (TTM) | $3.05 |
| Dividend Yield | - |
| Profit Margin | -26.49% |
| Revenue Growth | 2608.80% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $29.15 |
| 52-Week Low | $16.00 |
| 50-Day Avg | $19.00 |
| 200-Day Avg | $19.00 |
| Avg Volume | $1.15M |
| Volume | 408.0K |
Performance Analysis
BULLISHAPMD shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 50% of its 52-week range.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
P/E of 8.5 suggests the stock may be undervalued.
+
Strong revenue growth of 2608.8% year-over-year.
-
Operating at a loss with -26.5% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 03, 2026 15:57 UTC
Back to Screener Export Report